| Identification | Back Directory | [Name]
Ruthenium, tetrachlorobis(1H-indazole-κN2)-, (OC-6-11)- | [CAS]
783324-98-1 | [Synonyms]
BOLD-100
Ruthenium, tetrachlorobis(1H-indazole-κN2)-, (OC-6-11)- | [Molecular Formula]
C14H12Cl4N4Ru | [MOL File]
783324-98-1.mol | [Molecular Weight]
479.15 |
| Hazard Information | Back Directory | [Uses]
BOLD-100 (NKP-1339; IT-139) free base is a ruthenium-based anticancer agent. BOLD-100 free base also is an inhibitor of stress-induced GRP78 upregulation, disrupting endoplasmic reticulum (ER) homeostasis and inducing ER stress and unfolded protein response (UPR). BOLD-100 free base interferes with the complex interplay between ER-stress response, lysosome dynamics, and autophagy execution[1]. | [Biological Activity]
BOLD-100 is a ruthenium-based anticancer agent. BOLD-100 also is an inhibitor of stress-induced GRP78 upregulation, disrupting endoplasmic reticulum (ER) homeostasis and inducing ER stress and unfolded protein response (UPR). BOLD-100 interferes with the complex interplay between ER-stress response, lysosome dynamics, and autophagy execution[1]. | [References]
[1]. Baier D, et al. The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation. Pharmaceutics. 2022;14(2):238. Published 2022 Jan 20. |
|
|